Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.22 USD | -0.97% | -9.87% | +13.27% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 30.71M | Capitalization | 236M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -117M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.67 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-3.13
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.43% |
1 day | -3.12% | ||
1 week | -14.11% | ||
Current month | -21.10% | ||
1 month | -22.67% | ||
3 months | -13.56% | ||
6 months | +35.12% | ||
Current year | +14.37% |
Managers | Title | Age | Since |
---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 63 | 10-12-31 |
Daniel Calkins
DFI | Director of Finance/CFO | 37 | 18-11-30 |
Jonathan Pachter
CTO | Chief Tech/Sci/R&D Officer | 66 | 11-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 67 | 17-05-02 |
John Johnson
BRD | Director/Board Member | 66 | 20-04-22 |
Michael Kauffman
CHM | Chairman | 60 | 12-11-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.47% | 4 M€ | -5.15% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 9.22 | -0.97% | 35 728 |
24-04-24 | 9.31 | -3.12% | 79,258 |
24-04-23 | 9.61 | -1.33% | 101,636 |
24-04-22 | 9.74 | -1.02% | 95,499 |
24-04-19 | 9.84 | -3.81% | 151,397 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.37% | 236M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.78% | 22.2B | |
-16.53% | 21.23B | |
-9.00% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- VSTM Stock